Mostrar registro simples

dc.contributor.authorSchwartz, Ida Vanessa Doederleinpt_BR
dc.contributor.authorSouza, Monica Vinhas dept_BR
dc.contributor.authorLeivas, Paulo Gilberto Cogopt_BR
dc.contributor.authorFaccini, Lavinia Schulerpt_BR
dc.date.accessioned2017-05-23T02:26:38Zpt_BR
dc.date.issued2014pt_BR
dc.identifier.issn2357-9730pt_BR
dc.identifier.urihttp://hdl.handle.net/10183/158343pt_BR
dc.description.abstractThe implementation of a specific policy for rare diseases in the Brazilian Unified Health System presents challenges in terms of its rationale. Recognizing the importance of rarity in the context of public health means understanding genetics as one of the dimensions of disease and accepting that Brazil is undergoing a period of transition in health indicators. Although most rare diseases lack pharmacological treatment and genetic counseling constitutes the best strategy for their prevention, the cost of “orphan drugs” and their consequent lack of cost-effectiveness are still claimed as hurdles to the implementation of public policies in this field. Epidemiological aspects should not be used as isolated criteria for prioritization in public policies.en
dc.format.mimetypeapplication/pdfpt_BR
dc.language.isoengpt_BR
dc.relation.ispartofClinical and Biomedical Research. Vol. 34, no. 2 (2014), p. 122-131pt_BR
dc.rightsOpen Accessen
dc.subjectMedical geneticsen
dc.subjectDoenças raraspt_BR
dc.subjectMedicamentos órfãospt_BR
dc.subjectOrphan drugsen
dc.subjectRare diseasesen
dc.titleClinical genetics and public policies : how should rare diseases be managed?pt_BR
dc.typeArtigo de periódicopt_BR
dc.identifier.nrb000953674pt_BR
dc.type.originNacionalpt_BR


Thumbnail
   

Este item está licenciado na Creative Commons License

Mostrar registro simples